Cargando…

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis

Muscle involvement in AL amyloidosis is a rare condition, and the diagnosis of amyloid myopathy is often delayed and underdiagnosed. Amyloid myopathy may be the initial manifestation and may precede the diagnosis of systemic AL amyloidosis. Here, we report the case of a 73-year-old man who was refer...

Descripción completa

Detalles Bibliográficos
Autores principales: Accardi, Fabrizio, Papa, Valentina, Capozzi, Anna Rita, Capello, Gian Luca, Verga, Laura, Mancini, Cristina, Martella, Eugenia, Costa, Roberta, Notarfranchi, Laura, Dalla Palma, Benedetta, Aversa, Franco, Pietrini, Vladimiro, Cenacchi, Giovanna, Giuliani, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831914/
https://www.ncbi.nlm.nih.gov/pubmed/29651353
http://dx.doi.org/10.1155/2018/9840405
Descripción
Sumario:Muscle involvement in AL amyloidosis is a rare condition, and the diagnosis of amyloid myopathy is often delayed and underdiagnosed. Amyloid myopathy may be the initial manifestation and may precede the diagnosis of systemic AL amyloidosis. Here, we report the case of a 73-year-old man who was referred to our center for a monoclonal gammopathy of undetermined significance (MGUS) diagnosed since 1999. He reported a progressive weakness of proximal muscles of the legs with onset six months previously. Muscle biopsy showed mild histopathology featuring alterations of nonspecific type with a mixed myopathic and neurogenic involvement, and the diagnostic turning point was the demonstration of characteristic green birefringence under cross-polarized light following Congo red staining of perimysial vessels. Transmission electron microscopy (TEM) confirmed amyloid fibrils around perimysial vessels associated with collagen fibrils. A stepwise approach to diagnosis and staging of this disorder is critical and involves confirmation of amyloid deposition, identification of the fibril type, assessment of underlying amyloidogenic disorder, and evaluation of the extent and severity of amyloidotic organ involvement.